1. Methadone Use and the Risk of Hypoglycemia for Inpatients With Cancer Pain 
James H. Flory, MD, MSCE, Alison C. Wiesenthal, MD, Howard T. Thaler, PhD, Lauren Koranteng, PharmD, Natalie Moryl, MD 
Journal of Pain and Symptom Management 
Volume 51, Issue 1, Pages e1 (January 2016)
DOI: /j.jpainsymman
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions

2. Fig. 1
a) Adjusted odds ratio for hypoglycemia. b) Changes in blood glucose with time-varying exposures. *Denotes adjusted dose, reported as its equivalent in oral methadone. Reference category is days with no methadone or other opioid exposure.
Journal of Pain and Symptom Management  , e1DOI: ( /j.jpainsymman )
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions

3. Fig. 2
Time trends with higher dose (>40 mg/day equivalent dose, or PCA) versus lower dose (≤40 mg/day equivalent dose) methadone.
Journal of Pain and Symptom Management  , e1DOI: ( /j.jpainsymman )
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions

4. Supplementary Data
Primary analysis repeated after restriction to population of patients with no missing data. Panel 1 is odds ratio for hypoglycemia; panel 2 is change in lowest recorded serum glucose in mg/dL.*Denotes adjusted dose, reported as its equivalent in oral methadone.
Journal of Pain and Symptom Management  , e1DOI: ( /j.jpainsymman )
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions

5. Supplementary Data
Primary analysis repeated after restriction to population of patients with no missing data. Panel 1 is odds ratio for hypoglycemia; panel 2 is change in lowest recorded serum glucose in mg/dL.*Denotes adjusted dose, reported as its equivalent in oral methadone.
Journal of Pain and Symptom Management  , e1DOI: ( /j.jpainsymman )
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions